Compare Amphastar Pharmaceuticals Inc (AMPH) vs CDW Corp. (CDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs CDW Corp. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while CDW Corp. trades at $144.74 (market cap $18.45B). The key difference: CDW Corp. is far larger — about 22.3× Amphastar Pharmaceuticals Inc's market cap, and CDW Corp. pays a 1.75% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CDW | |
|---|---|---|
Market Cap | $826.08M | $18.45B |
Sector | Health | Technology |
52-Week High | $30.81 | $182.18 |
52-Week Low | $16.87 | $99.30 |
Enterprise Value | $1.22B | $23.66B |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
CDW trades at $144.39, up 2.98% today, near its pivot point of $139 with resistance at $143. The stock shows strong profitability with a 44.16% ROE and consistent earnings beats in recent quarters. Recent news highlights AI infrastructure demand fueling growth, while the company increased its share repurchase program by $1 billion in May 2026. Technical indicators are bullish, with moving averages supporting upward momentum.
Outlook remains positive driven by AI demand and shareholder returns, but risks include margin pressure and high debt. Analysts are bullish with a $142.17 consensus target and 71% buy ratings. Investors should monitor Q2 2026 earnings against the $2.80 EPS estimate for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About CDW Corp.
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →
